Game, Set & Match to Teva in Copaxone Affair

Terms of the VCU agreed to by Teva Canada and the PMPRB to end proceedings in the Copaxone matter reveal a significant win for Teva. Teva has agreed – without admission of excessive pricing – to pay a total fine of $248,222.32 to settle the matter.  That’s a whopping $2.6 million or 91% less than …

Continue reading ‘Game, Set & Match to Teva in Copaxone Affair’ »

Long Running Copaxone PMPRB Case to be Settled by VCU

BREAKING NEWS:  The PMPRB will release on its website later today the terms of a VCU that it has reached with Teva Canada to settle the long-running Copaxone dispute. A two-day Board Panel hearing on the matter had been scheduled to start on February 18th.  It would have been the third such hearing. The terms …

Continue reading ‘Long Running Copaxone PMPRB Case to be Settled by VCU’ »

A Closer Look at the PMPRB Moderate Improvement Designation

One aspect of the revised PMPRB Guidelines implemented in 2010 that was welcomed by the branded pharmaceutical industry was the change to the levels of therapeutic improvement.  Specifically, the old three category system was expanded to four distinct levels:  Breakthrough (BT), Significant Improvement (SI), Moderate Improvement (MI) and Slight or No improvement (SLNO). The creation …

Continue reading ‘A Closer Look at the PMPRB Moderate Improvement Designation’ »